Repligen Announces Identification Of Drug Target For Friedreich's Ataxia
Links shared publicly online about this topic.
- 1,721total visits
Repligen Announces Identification Of Drug Target For Friedreich's Ataxia
Repligen Corporation (Nasdaq: RGEN) reported publication of research that identifies histone deacetylase 3 (HDAC 3) as an important enzyme target for therapeutic intervention in Friedreich's ataxi
View full resource at medicalnewstoday.com
Tags: Drug
Most Recently Shared on September 26, 2009 at 12:13 pm By:
Repligen Announces Identification Of Drug Target For Friedreich's Ataxia: Repligen Corporation (Nasdaq: RGEN) r.. http://bit.ly/2nzX6O
Also Shared By:
Repligen Files Investigational New Drug Application With FDA For First Drug Targeting The Core Genetic Defect Of Friedreich's Ataxia
medicalnewstoday.com — “Repligen Corporation (Nasdaq: RGEN) announced that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective” View full resource at medicalnewstoday.com
Most Recently Shared on May 15, 2010 at 1:17 pm By:
Repligen Files Investigational New Drug Application With FDA For First Drug Targeting The Core Genetic Defect Of .... http://mnt.to/f/3CG4
Advertisement
MNT Neurology News
@mnt_neurology
Repligen Files Investigational New Drug Application With FDA For First Drug Targeting The Core Genetic Defect Of Fried... http://mnt.to/3CG4
1 year ago...